Allosteric regulation

Last updated

Allosteric regulation of an enzyme Enzyme Model.svg
Allosteric regulation of an enzyme

In biochemistry, allosteric regulation (or allosteric control) is the regulation of an enzyme by binding an effector molecule at a site other than the enzyme's active site.

Contents

The site to which the effector binds is termed the allosteric site or regulatory site. Allosteric sites allow effectors to bind to the protein, often resulting in a conformational change and/or a change in protein dynamics. [1] [2] Effectors that enhance the protein's activity are referred to as allosteric activators, whereas those that decrease the protein's activity are called allosteric inhibitors.

Allosteric regulations are a natural example of control loops, such as feedback from downstream products or feedforward from upstream substrates. Long-range allostery is especially important in cell signaling. [3] Allosteric regulation is also particularly important in the cell's ability to adjust enzyme activity.

The term allostery comes from the Ancient Greek allos ( ἄλλος ), "other", and stereos ( στερεός ), "solid (object)". This is in reference to the fact that the regulatory site of an allosteric protein is physically distinct from its active site. Allostery contrasts with substrate presentation which requires no conformational change for an enzyme's activation.

Models

A - Active site
B - Allosteric site
C - Substrate
D - Inhibitor
E - Enzyme
This is a diagram of allosteric regulation of an enzyme. Allosteric Regulation.svg
A – Active site
B – Allosteric site
C – Substrate
D – Inhibitor
E – Enzyme
This is a diagram of allosteric regulation of an enzyme.

Many allosteric effects can be explained by the concerted MWC model put forth by Monod, Wyman, and Changeux, [4] or by the sequential model (also known as the KNF model) described by Koshland, Nemethy, and Filmer. [5] Both postulate that protein subunits exist in one of two conformations, tensed (T) or relaxed (R), and that relaxed subunits bind substrate more readily than those in the tense state. The two models differ most in their assumptions about subunit interaction and the preexistence of both states. For proteins in which subunits exist in more than two conformations, the allostery landscape model described by Cuendet, Weinstein, and LeVine, [6] can be used. Allosteric regulation may be facilitated by the evolution of large-scale, low-energy conformational changes, which enables long-range allosteric interaction between distant binding sites. [7]

Concerted model

The concerted model of allostery, also referred to as the symmetry model or MWC model, postulates that enzyme subunits are connected in such a way that a conformational change in one subunit is necessarily conferred to all other subunits. Thus, all subunits must exist in the same conformation. The model further holds that, in the absence of any ligand (substrate or otherwise), the equilibrium favors one of the conformational states, T or R. The equilibrium can be shifted to the R or T state through the binding of one ligand (the allosteric effector or ligand) to a site that is different from the active site

Sequential model

The sequential model of allosteric regulation holds that subunits are not connected in such a way that a conformational change in one induces a similar change in the others. Thus, all enzyme subunits do not necessitate the same conformation. Moreover, the sequential model dictates that molecules of a substrate bind via an induced fit protocol. While such an induced fit converts a subunit from the tensed state to relaxed state, it does not propagate the conformational change to adjacent subunits. Instead, substrate-binding at one subunit only slightly alters the structure of other subunits so that their binding sites are more receptive to substrate. To summarize:

Morpheein model

The morpheein model of allosteric regulation is a dissociative concerted model. [8]

A morpheein is a homo-oligomeric structure that can exist as an ensemble of physiologically significant and functionally different alternate quaternary assemblies. Transitions between alternate morpheein assemblies involve oligomer dissociation, conformational change in the dissociated state, and reassembly to a different oligomer. The required oligomer disassembly step differentiates the morpheein model for allosteric regulation from the classic MWC and KNF models.

Porphobilinogen synthase (PBGS) is the prototype morpheein.

Ensemble models

Ensemble models of allosteric regulation enumerate an allosteric system's statistical ensemble as a function of its potential energy function, and then relate specific statistical measurements of allostery to specific energy terms in the energy function (such as an intermolecular salt bridge between two domains). [9] Ensemble models like the ensemble allosteric model [10] and allosteric Ising model [11] assume that each domain of the system can adopt two states similar to the MWC model. The allostery landscape model introduced by Cuendet, Weinstein, and LeVine [6] allows for the domains to have any number of states and the contribution of a specific molecular interaction to a given allosteric coupling can be estimated using a rigorous set of rules. Molecular dynamics simulations can be used to estimate a system's statistical ensemble so that it can be analyzed with the allostery landscape model.

Allosteric modulation

Allosteric modulation is used to alter the activity of molecules and enzymes in biochemistry and pharmacology. For comparison, a typical drug is made to bind to the active site of an enzyme which thus prohibits binding of a substrate to that enzyme causing a decrease in enzyme activity. Allosteric modulation occurs when an effector binds to an allosteric site (also known as a regulatory site) of an enzyme and alters the enzyme activity. Allosteric modulators are designed to fit the allosteric site to cause a conformational change of the enzyme, in particular a change in the shape of the active site, which then causes a change in its activity. In contrast to typical drugs, modulators are not competitive inhibitors. They can be positive (activating) causing an increase of the enzyme activity or negative (inhibiting) causing a decrease of the enzyme activity. The use of allosteric modulation allows the control of the effects of specific enzyme activities; as a result, allosteric modulators are very effective in pharmacology. [12] In a biological system, allosteric modulation can be difficult to distinguish from modulation by substrate presentation.

Energy sensing model

An example of this model is seen with the Mycobacterium tuberculosis , a bacterium that is perfectly suited to adapt to living in the macrophages of humans. The enzyme's sites serve as a communication between different substrates. Specifically between AMP and G6P. Sites like these also serve as a sensing mechanism for the enzyme's performance. [13]

Positive modulation

Positive allosteric modulation (also known as allosteric activation) occurs when the binding of one ligand enhances the attraction between substrate molecules and other binding sites. An example is the binding of oxygen molecules to hemoglobin, where oxygen is effectively both the substrate and the effector. The allosteric, or "other", site is the active site of an adjoining protein subunit. The binding of oxygen to one subunit induces a conformational change in that subunit that interacts with the remaining active sites to enhance their oxygen affinity. Another example of allosteric activation is seen in cytosolic IMP-GMP specific 5'-nucleotidase II (cN-II), where the affinity for substrate GMP increases upon GTP binding at the dimer interface.

Negative modulation

Negative allosteric modulation (also known as allosteric inhibition) occurs when the binding of one ligand decreases the affinity for substrate at other active sites. For example, when 2,3-BPG binds to an allosteric site on hemoglobin, the affinity for oxygen of all subunits decreases. This is when a regulator is absent from the binding site.

Direct thrombin inhibitors provides an excellent example of negative allosteric modulation. Allosteric inhibitors of thrombin have been discovered that could potentially be used as anticoagulants.

Another example is strychnine, a convulsant poison, which acts as an allosteric inhibitor of the glycine receptor. Glycine is a major post-synaptic inhibitory neurotransmitter in mammalian spinal cord and brain stem. Strychnine acts at a separate binding site on the glycine receptor in an allosteric manner; i.e., its binding lowers the affinity of the glycine receptor for glycine. Thus, strychnine inhibits the action of an inhibitory transmitter, leading to convulsions.

Another instance in which negative allosteric modulation can be seen is between ATP and the enzyme phosphofructokinase within the negative feedback loop that regulates glycolysis. Phosphofructokinase (generally referred to as PFK) is an enzyme that catalyses the third step of glycolysis: the phosphorylation of fructose-6-phosphate into fructose 1,6-bisphosphate. PFK can be allosterically inhibited by high levels of ATP within the cell. When ATP levels are high, ATP will bind to an allosteric site on phosphofructokinase, causing a change in the enzyme's three-dimensional shape. This change causes its affinity for substrate (fructose-6-phosphate and ATP) at the active site to decrease, and the enzyme is deemed inactive. This causes glycolysis to cease when ATP levels are high, thus conserving the body's glucose and maintaining balanced levels of cellular ATP. In this way, ATP serves as a negative allosteric modulator for PFK, despite the fact that it is also a substrate of the enzyme.

Types

Homotropic

A homotropic allosteric modulator is a substrate for its target protein, as well as a regulatory molecule of the protein's activity. It is typically an activator of the protein. [14] For example, O2 and CO are homotropic allosteric modulators of hemoglobin. Likewise, in IMP/GMP specific 5' nucleotidase, binding of one GMP molecule to a single subunit of the tetrameric enzyme leads to increased affinity for GMP by the subsequent subunits as revealed by sigmoidal substrate versus velocity plots. [14]

Heterotropic

A heterotropic allosteric modulator is a regulatory molecule that is not the enzyme's substrate. It may be either an activator or an inhibitor of the enzyme. For example, H+, CO2, and 2,3-bisphosphoglycerate are heterotropic allosteric modulators of hemoglobin. [15] Once again, in IMP/GMP specific 5' nucleotidase, binding of GTP molecule at the dimer interface in the tetrameric enzyme leads to increased affinity for substrate GMP at the active site indicating towards K-type heterotropic allosteric activation. [14]

As has been amply highlighted above, some allosteric proteins can be regulated by both their substrates and other molecules. Such proteins are capable of both homotropic and heterotropic interactions. [14]

Essential activators

Some allosteric activators are referred to as "essential", or "obligate" activators, in the sense that in their absence, the activity of their target enzyme activity is very low or negligible, as is the case with N-acetylglutamate's activity on carbamoyl phosphate synthetase I, for example. [16] [17]

Non-regulatory allostery

A non-regulatory allosteric site is any non-regulatory component of an enzyme (or any protein), that is not itself an amino acid. For instance, many enzymes require sodium binding to ensure proper function. However, the sodium does not necessarily act as a regulatory subunit; the sodium is always present and there are no known biological processes to add/remove sodium to regulate enzyme activity. Non-regulatory allostery could comprise any other ions besides sodium (calcium, magnesium, zinc), as well as other chemicals and possibly vitamins.

Pharmacology

Allosteric modulation of a receptor results from the binding of allosteric modulators at a different site (a "regulatory site") from that of the endogenous ligand (an "active site") and enhances or inhibits the effects of the endogenous ligand. Under normal circumstances, it acts by causing a conformational change in a receptor molecule, which results in a change in the binding affinity of the ligand. In this way, an allosteric ligand modulates the receptor's activation by its primary orthosteric ligand, and can be thought to act like a dimmer switch in an electrical circuit, adjusting the intensity of the response.

For example, the GABAA receptor has two active sites that the neurotransmitter gamma-aminobutyric acid (GABA) binds, but also has benzodiazepine and general anaesthetic agent regulatory binding sites. These regulatory sites can each produce positive allosteric modulation, potentiating the activity of GABA. Diazepam is a positive allosteric modulator at the benzodiazepine regulatory site, and its antidote flumazenil is a receptor antagonist.

More recent examples of drugs that allosterically modulate their targets include the calcium-mimicking cinacalcet and the HIV treatment maraviroc.

Allosteric sites as drug targets

Allosteric proteins are involved in, and are central in many diseases, [18] [19] and allosteric sites may represent a novel drug target. There are a number of advantages in using allosteric modulators as preferred therapeutic agents over classic orthosteric ligands. For example, G protein-coupled receptor (GPCR) allosteric binding sites have not faced the same evolutionary pressure as orthosteric sites to accommodate an endogenous ligand, so are more diverse. [20] Therefore, greater GPCR selectivity may be obtained by targeting allosteric sites. [20] This is particularly useful for GPCRs where selective orthosteric therapy has been difficult because of sequence conservation of the orthosteric site across receptor subtypes. [21] Also, these modulators have a decreased potential for toxic effects, since modulators with limited co-operativity will have a ceiling level to their effect, irrespective of the administered dose. [20] Another type of pharmacological selectivity that is unique to allosteric modulators is based on co-operativity. An allosteric modulator may display neutral co-operativity with an orthosteric ligand at all subtypes of a given receptor except the subtype of interest, which is termed "absolute subtype selectivity". [21] If an allosteric modulator does not possess appreciable efficacy, it can provide another powerful therapeutic advantage over orthosteric ligands, namely the ability to selectively tune up or down tissue responses only when the endogenous agonist is present. [21] Oligomer-specific small molecule binding sites are drug targets for medically relevant morpheeins. [22]

Synthetic allosteric systems

There are many synthetic compounds containing several noncovalent binding sites, which exhibit conformational changes upon occupation of one site. Cooperativity between single binding contributions in such supramolecular systems is positive if occupation of one binding site enhances the affinity ΔG at a second site, and negative if the affinity isn't highered. Most synthetic allosteric complexes rely on conformational reorganization upon the binding of one effector ligand which then leads to either enhanced or weakened association of second ligand at another binding site. [23] [24] [25] Conformational coupling between several binding sites is in artificial systems usually much larger than in proteins with their usually larger flexibility. The parameter which determines the efficiency (as measured by the ratio of equilibrium constants Krel = KA(E)/KA in presence and absence of an effector E ) is the conformational energy needed to adopt a closed or strained conformation for the binding of a ligand A. [26]

In many multivalent supramolecular systems [27] direct interaction between bound ligands can occur, which can lead to large cooperativities. Most common is such a direct interaction between ions in receptors for ion-pairs. [28] [29] This cooperativity is often also referred to as allostery, even though conformational changes here are not necessarily triggering binding events.

Online resources

Allosteric Database

Allostery is a direct and efficient means for regulation of biological macromolecule function, produced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the often high receptor selectivity and lower target-based toxicity, allosteric regulation is also expected to play an increasing role in drug discovery and bioengineering. The AlloSteric Database (ASD) [30] provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow the prediction of allostery for unknown proteins, to be followed with experimental validation. In addition, modulators curated in ASD can be used to investigate potential allosteric targets for a query compound, and can help chemists to implement structure modifications for novel allosteric drug design.

Allosteric residues and their prediction

Not all protein residues play equally important roles in allosteric regulation. The identification of residues that are essential to allostery (so-called “allosteric residues”) has been the focus of many studies, especially within the last decade. [31] [32] [33] [34] [35] [36] [37] [38] In part, this growing interest is a result of their general importance in protein science, but also because allosteric residues may be exploited in biomedical contexts. Pharmacologically important proteins with difficult-to-target sites may yield to approaches in which one alternatively targets easier-to-reach residues that are capable of allosterically regulating the primary site of interest. [39] These residues can broadly be classified as surface- and interior-allosteric amino acids. Allosteric sites at the surface generally play regulatory roles that are fundamentally distinct from those within the interior; surface residues may serve as receptors or effector sites in allosteric signal transmission, whereas those within the interior may act to transmit such signals. [40] [41]

See also

Related Research Articles

<span class="mw-page-title-main">G protein-coupled receptor</span> Class of cell surface receptors coupled to G-protein-associated intracellular signaling

G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptors, and G protein-linked receptors (GPLR), form a large group of evolutionarily related proteins that are cell surface receptors that detect molecules outside the cell and activate cellular responses. They are coupled with G proteins. They pass through the cell membrane seven times in the form of six loops of amino acid residues, which is why they are sometimes referred to as seven-transmembrane receptors. Ligands can bind either to the extracellular N-terminus and loops or to the binding site within transmembrane helices. They are all activated by agonists, although a spontaneous auto-activation of an empty receptor has also been observed.

Cooperative binding occurs in molecular binding systems containing more than one type, or species, of molecule and in which one of the partners is not mono-valent and can bind more than one molecule of the other species. In general, molecular binding is an interaction between molecules that results in a stable physical association between those molecules.

<span class="mw-page-title-main">Protein kinase A</span> Family of enzymes

In cell biology, protein kinase A (PKA) is a family of serine-threonine kinase whose activity is dependent on cellular levels of cyclic AMP (cAMP). PKA is also known as cAMP-dependent protein kinase. PKA has several functions in the cell, including regulation of glycogen, sugar, and lipid metabolism. It should not be confused with 5'-AMP-activated protein kinase.

<span class="mw-page-title-main">Phosphofructokinase 1</span> Class of enzymes

Phosphofructokinase-1 (PFK-1) is one of the most important regulatory enzymes of glycolysis. It is an allosteric enzyme made of 4 subunits and controlled by many activators and inhibitors. PFK-1 catalyzes the important "committed" step of glycolysis, the conversion of fructose 6-phosphate and ATP to fructose 1,6-bisphosphate and ADP. Glycolysis is the foundation for respiration, both anaerobic and aerobic. Because phosphofructokinase (PFK) catalyzes the ATP-dependent phosphorylation to convert fructose-6-phosphate into fructose 1,6-bisphosphate and ADP, it is one of the key regulatory steps of glycolysis. PFK is able to regulate glycolysis through allosteric inhibition, and in this way, the cell can increase or decrease the rate of glycolysis in response to the cell's energy requirements. For example, a high ratio of ATP to ADP will inhibit PFK and glycolysis. The key difference between the regulation of PFK in eukaryotes and prokaryotes is that in eukaryotes PFK is activated by fructose 2,6-bisphosphate. The purpose of fructose 2,6-bisphosphate is to supersede ATP inhibition, thus allowing eukaryotes to have greater sensitivity to regulation by hormones like glucagon and insulin.

<span class="mw-page-title-main">Binding site</span> Molecule-specific coordinate bonding area in biological systems

In biochemistry and molecular biology, a binding site is a region on a macromolecule such as a protein that binds to another molecule with specificity. The binding partner of the macromolecule is often referred to as a ligand. Ligands may include other proteins, enzyme substrates, second messengers, hormones, or allosteric modulators. The binding event is often, but not always, accompanied by a conformational change that alters the protein's function. Binding to protein binding sites is most often reversible, but can also be covalent reversible or irreversible.

<span class="mw-page-title-main">Receptor (biochemistry)</span> Protein molecule receiving signals for a cell

In biochemistry and pharmacology, receptors are chemical structures, composed of protein, that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to a receptor and produce physiological responses such as change in the electrical activity of a cell. For example, GABA, an inhibitory neurotransmitter, inhibits electrical activity of neurons by binding to GABAA receptors. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway.

<span class="mw-page-title-main">Insulin receptor</span> Mammalian protein found in Homo sapiens

The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of receptor tyrosine kinase. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis; a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.

GABA<sub>A</sub> receptor Ionotropic receptor and ligand-gated ion channel

The GABAA receptor (GABAAR) is an ionotropic receptor and ligand-gated ion channel. Its endogenous ligand is γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Accurate regulation of GABAergic transmission through appropriate developmental processes, specificity to neural cell types, and responsiveness to activity is crucial for the proper functioning of nearly all aspects of the central nervous system (CNS). Upon opening, the GABAA receptor on the postsynaptic cell is selectively permeable to chloride ions (Cl) and, to a lesser extent, bicarbonate ions (HCO3).

A regulatory enzyme is an enzyme in a biochemical pathway which, through its responses to the presence of certain other biomolecules, regulates the pathway activity. This is usually done for pathways whose products may be needed in different amounts at different times, such as hormone production. Regulatory enzymes exist at high concentrations so their activity can be increased or decreased with changes in substrate concentrations.

<span class="mw-page-title-main">Ligand (biochemistry)</span> Substance that forms a complex with a biomolecule

In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. The etymology stems from Latin ligare, which means 'to bind'. In protein-ligand binding, the ligand is usually a molecule which produces a signal by binding to a site on a target protein. The binding typically results in a change of conformational isomerism (conformation) of the target protein. In DNA-ligand binding studies, the ligand can be a small molecule, ion, or protein which binds to the DNA double helix. The relationship between ligand and binding partner is a function of charge, hydrophobicity, and molecular structure.

<span class="mw-page-title-main">Monod–Wyman–Changeux model</span> Biochemical model of protein transitions

In biochemistry, the Monod–Wyman–Changeux model describes allosteric transitions of proteins made up of identical subunits. It was proposed by Jean-Pierre Changeux in his PhD thesis, and described by Jacques Monod, Jeffries Wyman, and Jean-Pierre Changeux. It contrasts with the sequential model and substrate presentation.

<span class="mw-page-title-main">Glutamate dehydrogenase 1</span> Enzyme

GLUD1 is a mitochondrial matrix enzyme, one of the family of glutamate dehydrogenases that are ubiquitous in life, with a key role in nitrogen and glutamate (Glu) metabolism and energy homeostasis. This dehydrogenase is expressed at high levels in liver, brain, pancreas and kidney, but not in muscle. In the pancreatic cells, GLUD1 is thought to be involved in insulin secretion mechanisms. In nervous tissue, where glutamate is present in concentrations higher than in the other tissues, GLUD1 appears to function in both the synthesis and the catabolism of glutamate and perhaps in ammonia detoxification.

Allosteric enzymes are enzymes that change their conformational ensemble upon binding of an effector which results in an apparent change in binding affinity at a different ligand binding site. This "action at a distance" through binding of one ligand affecting the binding of another at a distinctly different site, is the essence of the allosteric concept. Allostery plays a crucial role in many fundamental biological processes, including but not limited to cell signaling and the regulation of metabolism. Allosteric enzymes need not be oligomers as previously thought, and in fact many systems have demonstrated allostery within single enzymes. In biochemistry, allosteric regulation is the regulation of a protein by binding an effector molecule at a site other than the enzyme's active site.

<span class="mw-page-title-main">Sequential model</span> Type of model used in biochemistry

The sequential model is a theory that describes cooperativity of protein subunits. It postulates that a protein's conformation changes with each binding of a ligand, thus sequentially changing its affinity for the ligand at neighboring binding sites. It gives one explanation for cooperative binding.

Receptor theory is the application of receptor models to explain drug behavior. Pharmacological receptor models preceded accurate knowledge of receptors by many years. John Newport Langley and Paul Ehrlich introduced the concept that receptors can mediate drug action at the beginning of the 20th century. Alfred Joseph Clark was the first to quantify drug-induced biological responses. So far, nearly all of the quantitative theoretical modelling of receptor function has centred on ligand-gated ion channels and G protein-coupled receptors.

<span class="mw-page-title-main">Morpheein</span> Model of protein allosteric regulation

Morpheeins are proteins that can form two or more different homo-oligomers, but must come apart and change shape to convert between forms. The alternate shape may reassemble to a different oligomer. The shape of the subunit dictates which oligomer is formed. Each oligomer has a finite number of subunits (stoichiometry). Morpheeins can interconvert between forms under physiological conditions and can exist as an equilibrium of different oligomers. These oligomers are physiologically relevant and are not misfolded protein; this distinguishes morpheeins from prions and amyloid. The different oligomers have distinct functionality. Interconversion of morpheein forms can be a structural basis for allosteric regulation, an idea noted many years ago, and later revived. A mutation that shifts the normal equilibrium of morpheein forms can serve as the basis for a conformational disease. Features of morpheeins can be exploited for drug discovery. The dice image represents a morpheein equilibrium containing two different monomeric shapes that dictate assembly to a tetramer or a pentamer. The one protein that is established to function as a morpheein is porphobilinogen synthase, though there are suggestions throughout the literature that other proteins may function as morpheeins.

<span class="mw-page-title-main">Cell surface receptor</span> Class of ligand activated receptors localized in surface of plama cell membrane

Cell surface receptors are receptors that are embedded in the plasma membrane of cells. They act in cell signaling by receiving extracellular molecules. They are specialized integral membrane proteins that allow communication between the cell and the extracellular space. The extracellular molecules may be hormones, neurotransmitters, cytokines, growth factors, cell adhesion molecules, or nutrients; they react with the receptor to induce changes in the metabolism and activity of a cell. In the process of signal transduction, ligand binding affects a cascading chemical change through the cell membrane.

In pharmacology and biochemistry, allosteric modulators are a group of substances that bind to a receptor to change that receptor's response to stimuli. Some of them, like benzodiazepines or alcoholic beverages, function as psychoactive drugs. The site that an allosteric modulator binds to is not the same one to which an endogenous agonist of the receptor would bind. Modulators and agonists can both be called receptor ligands.

Allostery is the most direct and efficient way for regulation of biological macromolecule function induced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the inherent high receptor selectivity and lower target-based toxicity, it is also expected to play a more positive role in drug discovery and bioengineering, leading to rapid growth on allosteric findings.

A receptor modulator, or receptor ligand, is a general term for a substance, endogenous or exogenous, that binds to and regulates the activity of chemical receptors. They are ligands that can act on different parts of receptors and regulate activity in a positive, negative, or neutral direction with varying degrees of efficacy. Categories of these modulators include receptor agonists and receptor antagonists, as well as receptor partial agonists, inverse agonists, orthosteric modulators, and allosteric modulators, Examples of receptor modulators in modern medicine include CFTR modulators, selective androgen receptor modulators (SARMs), and muscarinic ACh receptor modulators.

References

  1. Cooper A, Dryden DT (October 1984). "Allostery without conformational change. A plausible model". European Biophysics Journal. 11 (2): 103–109. doi:10.1007/BF00276625. PMID   6544679. S2CID   12591175.
  2. Liu J, Nussinov R (June 2016). "Allostery: An Overview of Its History, Concepts, Methods, and Applications". PLOS Computational Biology. 12 (6): e1004966. Bibcode:2016PLSCB..12E4966L. doi: 10.1371/journal.pcbi.1004966 . PMC   4890769 . PMID   27253437. S2CID   3610740.
  3. Bu Z, Callaway DJ (2011). "Proteins move! Protein dynamics and long-range allostery in cell signaling". Protein Structure and Diseases. Advances in Protein Chemistry and Structural Biology. Vol. 83. pp. 163–221. doi:10.1016/B978-0-12-381262-9.00005-7. ISBN   9780123812629. PMID   21570668.
  4. Monod J, Wyman J, Changeux JP (May 1965). "On the nature of allosteric transitions:A plausible model". Journal of Molecular Biology. 12: 88–118. doi:10.1016/s0022-2836(65)80285-6. PMID   14343300.
  5. Koshland DE, Némethy G, Filmer D (January 1966). "Comparison of experimental binding data and theoretical models in proteins containing subunits". Biochemistry. 5 (1): 365–85. doi:10.1021/bi00865a047. PMID   5938952.
  6. 1 2 Cuendet MA, Weinstein H, LeVine MV (December 2016). "The Allostery Landscape: Quantifying Thermodynamic Couplings in Biomolecular Systems". Journal of Chemical Theory and Computation. 12 (12): 5758–5767. doi:10.1021/acs.jctc.6b00841. PMC   5156960 . PMID   27766843.
  7. Eckmann JP, Rougemont J, Tlusty T (July 30, 2019). "Colloquium : Proteins: The physics of amorphous evolving matter". Reviews of Modern Physics. 91 (3): 031001. arXiv: 1907.13371 . Bibcode:2019RvMP...91c1001E. doi:10.1103/RevModPhys.91.031001. ISSN   0034-6861. S2CID   199001124.
  8. Jaffe EK (September 2005). "Morpheeins--a new structural paradigm for allosteric regulation". Trends in Biochemical Sciences. 30 (9): 490–7. doi:10.1016/j.tibs.2005.07.003. PMID   16023348.
  9. Motlagh HN, Wrabl JO, Li J, Hilser VJ (April 2014). "The ensemble nature of allostery". Nature. 508 (7496): 331–9. Bibcode:2014Natur.508..331M. doi:10.1038/nature13001. PMC   4224315 . PMID   24740064.
  10. Hilser VJ, Wrabl JO, Motlagh HN (2012). "Structural and energetic basis of allostery". Annual Review of Biophysics. 41: 585–609. doi:10.1146/annurev-biophys-050511-102319. PMC   3935618 . PMID   22577828.
  11. LeVine MV, Weinstein H (May 2015). "AIM for Allostery: Using the Ising Model to Understand Information Processing and Transmission in Allosteric Biomolecular Systems". Entropy. 17 (5): 2895–2918. Bibcode:2015Entrp..17.2895L. doi: 10.3390/e17052895 . PMC   4652859 . PMID   26594108.
  12. Abdel-Magid AF (February 2015). "Allosteric modulators: an emerging concept in drug discovery". ACS Medicinal Chemistry Letters. 6 (2): 104–7. doi:10.1021/ml5005365. PMC   4329591 . PMID   25699154.
  13. Zhong W, Cui L, Goh BC, Cai Q, Ho P, Chionh YH, Yuan M, Sahili AE, Fothergill-Gilmore LA, Walkinshaw MD, Lescar J, Dedon PC (December 2017). "Allosteric pyruvate kinase-based "logic gate" synergistically senses energy and sugar levels in Mycobacterium tuberculosis". Nature Communications. 8 (1): 1986. Bibcode:2017NatCo...8.1986Z. doi:10.1038/s41467-017-02086-y. PMC   5719368 . PMID   29215013.
  14. 1 2 3 4 Srinivasan B, Forouhar F, Shukla A, Sampangi C, Kulkarni S, Abashidze M, Seetharaman J, Lew S, Mao L, Acton TB, Xiao R, Everett JK, Montelione GT, Tong L, Balaram H (March 2014). "Allosteric regulation and substrate activation in cytosolic nucleotidase II from Legionella pneumophila". The FEBS Journal. 281 (6): 1613–1628. doi:10.1111/febs.12727. PMC   3982195 . PMID   24456211.
  15. Edelstein SJ (1975). "Cooperative interactions of hemoglobin". Annual Review of Biochemistry. 44: 209–32. doi:10.1146/annurev.bi.44.070175.001233. PMID   237460.
  16. Shi D, Allewell NM, Tuchman M (June 2015). "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms". International Journal of Molecular Sciences. 16 (6): 13004–22. doi: 10.3390/ijms160613004 . PMC   4490483 . PMID   26068232.
  17. de Cima S, Polo LM, Díez-Fernández C, Martínez AI, Cervera J, Fita I, Rubio V (November 2015). "Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis". Scientific Reports. 5 (1): 16950. Bibcode:2015NatSR...516950D. doi:10.1038/srep16950. PMC   4655335 . PMID   26592762.
  18. Nussinov R, Tsai C (2013). "Allostery in disease and in drug discovery". Cell. 153 (2): 293–305. doi: 10.1016/j.cell.2013.03.034 . PMID   23582321.
  19. Abrusan G, Ascher DB, Inouye M (2022). "Known allosteric proteins have central roles in genetic disease". PLOS Computational Biology. 18 (2): e1009806. arXiv: 2107.04318 . Bibcode:2022PLSCB..18E9806A. doi: 10.1371/journal.pcbi.1009806 . PMID   10138267.
  20. 1 2 3 Christopoulos A, May LT, Avlani VA, Sexton PM (November 2004). "G-protein-coupled receptor allosterism: the promise and the problem(s)". Biochemical Society Transactions. 32 (Pt 5): 873–7. doi:10.1042/BST0320873. PMID   15494038.
  21. 1 2 3 May LT, Leach K, Sexton PM, Christopoulos A (2007). "Allosteric modulation of G protein-coupled receptors". Annual Review of Pharmacology and Toxicology. 47: 1–51. doi:10.1146/annurev.pharmtox.47.120505.105159. PMID   17009927.
  22. Jaffe EK (2010). "Morpheeins – A New Pathway for Allosteric Drug Discovery~!2010-02-12~!2010-05-21~!2010-06-08~!". The Open Conference Proceedings Journal. 1: 1–6. doi: 10.2174/2210289201001010001 (inactive March 11, 2024). PMC   3107518 . PMID   21643557.{{cite journal}}: CS1 maint: DOI inactive as of March 2024 (link)
  23. Takeuchi M, Ikeda M, Sugasaki A, Shinkai S (November 2001). "Molecular design of artificial molecular and ion recognition systems with allosteric guest responses". Accounts of Chemical Research. 34 (11): 865–73. doi:10.1021/ar0000410. PMID   11714258.
  24. Kremer C, Lützen A (May 2013). "Artificial allosteric receptors". Chemistry: A European Journal. 19 (20): 6162–96. doi:10.1002/chem.201203814. PMID   23463705.
  25. Kovbasyuk L, Krämer R (June 2004). "Allosteric supramolecular receptors and catalysts". Chemical Reviews. 104 (6): 3161–87. doi:10.1021/cr030673a. PMID   15186190.
  26. Schneider HJ (September 2016). "Efficiency parameters in artificial allosteric systems". Organic & Biomolecular Chemistry. 14 (34): 7994–8001. doi:10.1039/c6ob01303a. PMID   27431438.
  27. Badjić JD, Nelson A, Cantrill SJ, Turnbull WB, Stoddart JF (September 2005). "Multivalency and cooperativity in supramolecular chemistry". Accounts of Chemical Research. 38 (9): 723–32. doi:10.1021/ar040223k. PMID   16171315.
  28. Kim SK, Sessler JL (October 2010). "Ion pair receptors". Chemical Society Reviews. 39 (10): 3784–809. doi:10.1039/c002694h. PMC   3016456 . PMID   20737073.
  29. McConnell AJ, Beer PD (May 2012). "Heteroditopic receptors for ion-pair recognition". Angewandte Chemie. 51 (21): 5052–61. doi:10.1002/anie.201107244. PMID   22419667.
  30. Huang Z, Zhu L, Cao Y, Wu G, Liu X, Chen Y, Wang Q, Shi T, Zhao Y, Wang Y, Li W, Li Y, Chen H, Chen G, Zhang J (January 2011). "ASD: a comprehensive database of allosteric proteins and modulators". Nucleic Acids Research. 39 (Database issue): D663–9. doi:10.1093/nar/gkq1022. PMC   3013650 . PMID   21051350.
  31. Panjkovich A, Daura X (October 2012). "Exploiting protein flexibility to predict the location of allosteric sites". BMC Bioinformatics. 13: 273. doi: 10.1186/1471-2105-13-273 . PMC   3562710 . PMID   23095452.
  32. Süel GM, Lockless SW, Wall MA, Ranganathan R (January 2003). "Evolutionarily conserved networks of residues mediate allosteric communication in proteins". Nature Structural Biology. 10 (1): 59–69. doi:10.1038/nsb881. PMID   12483203. S2CID   67749580.
  33. Mitternacht S, Berezovsky IN (September 2011). "Binding leverage as a molecular basis for allosteric regulation". PLOS Computational Biology. 7 (9): e1002148. Bibcode:2011PLSCB...7E2148M. doi: 10.1371/journal.pcbi.1002148 . PMC   3174156 . PMID   21935347.
  34. Gasper PM, Fuglestad B, Komives EA, Markwick PR, McCammon JA (December 2012). "Allosteric networks in thrombin distinguish procoagulant vs. anticoagulant activities". Proceedings of the National Academy of Sciences of the United States of America. 109 (52): 21216–22. doi: 10.1073/pnas.1218414109 . PMC   3535651 . PMID   23197839.
  35. Ghosh A, Vishveshwara S (November 2008). "Variations in clique and community patterns in protein structures during allosteric communication: investigation of dynamically equilibrated structures of methionyl tRNA synthetase complexes". Biochemistry. 47 (44): 11398–407. doi:10.1021/bi8007559. PMID   18842003.
  36. Sethi A, Eargle J, Black AA, Luthey-Schulten Z (April 2009). "Dynamical networks in tRNA:protein complexes". Proceedings of the National Academy of Sciences of the United States of America. 106 (16): 6620–5. Bibcode:2009PNAS..106.6620S. doi: 10.1073/pnas.0810961106 . PMC   2672494 . PMID   19351898.
  37. Vanwart AT, Eargle J, Luthey-Schulten Z, Amaro RE (August 2012). "Exploring residue component contributions to dynamical network models of allostery". Journal of Chemical Theory and Computation. 8 (8): 2949–2961. doi:10.1021/ct300377a. PMC   3489502 . PMID   23139645.
  38. Rivalta I, Sultan MM, Lee NS, Manley GA, Loria JP, Batista VS (May 2012). "Allosteric pathways in imidazole glycerol phosphate synthase". Proceedings of the National Academy of Sciences of the United States of America. 109 (22): E1428–36. doi: 10.1073/pnas.1120536109 . PMC   3365145 . PMID   22586084.
  39. Negre CF, Morzan UN, Hendrickson HP, Pal R, Lisi GP, Loria JP, Rivalta I, Ho J, Batista VS (December 2018). "Eigenvector centrality for characterization of protein allosteric pathways". Proceedings of the National Academy of Sciences of the United States of America. 115 (52): E12201–E12208. arXiv: 1706.02327 . Bibcode:2018PNAS..11512201N. doi: 10.1073/pnas.1810452115 . PMC   6310864 . PMID   30530700.
  40. Clarke D, Sethi A, Li S, Kumar S, Chang RW, Chen J, Gerstein M (May 2016). "Identifying Allosteric Hotspots with Dynamics: Application to Inter- and Intra-species Conservation". Structure. 24 (5): 826–837. doi:10.1016/j.str.2016.03.008. PMC   4883016 . PMID   27066750.
  41. Dutta S, Eckmann JP, Libchaber A, Tlusty T (May 2018). "Green function of correlated genes in a minimal mechanical model of protein evolution". Proceedings of the National Academy of Sciences of the United States of America. 115 (20): E4559–E4568. arXiv: 1801.03681 . Bibcode:2018PNAS..115E4559D. doi: 10.1073/pnas.1716215115 . PMC   5960285 . PMID   29712824.